title: Coronary stenting is associated with an acute increase in plasma myeloperoxidase in stable angina patients but not in patients with acute myocardial infarction.
abstract: BACKGROUND
  Myeloperoxidase (MPO) has emerged as a critical mediator in the physiopathology of atherosclerosis from plaque formation and growth until destabilization and rupture leading to acute coronary syndrome (ACS). Using coronary stenting as a model of plaque injury, we aimed to determine the evolution of systemic MPO levels following coronary stenting in stable angina patients and in patients with acute myocardial infarction (AMI).
  
  
  METHODS
  Plasma levels of MPO, lactoferrin, interleukin (IL)-6, C-reactive protein and PMN counts were assessed in 13 patients with Non-ST-elevation myocardial infarction (NSTEMI) (Group A) and in 29 patients with stable angina pectoris (Group B), undergoing coronary stenting. Serial blood samples were taken before angioplasty (baseline) and at 1, 6 and 24 h following initial balloon inflation.
  
  
  RESULTS
  Following angioplasty, the overall plasma MPO levels significantly increased at 1 h in group B (120.5+/-79.0 to 166+/-79.5, p=0.003) but not in group A (121+/-63.4 to 124.7+/-76.9, p=0.753). In Group B, the increase in MPO levels at 1 h were significantly higher in the presence of complex lesions compared to patients with simple lesions (p=0.023). Lactoferrin levels showed no change over time except for a significant decrease at 6 h in group B.
  
  
  CONCLUSIONS
  In stable angina patients, coronary stenting is associated with an acute and transient increase in plasma MPO levels, but not in lactoferrin levels, with an enhanced response in the presence of complex lesions. In contrast, we observed no changes in plasma MPO and lactoferrin levels following stenting in patients with AMI. Given its pro-inflammatory properties, the potential implication of MPO release on clinical outcome in stable patients undergoing stenting needs further investigation.
authors.affiliation: Division of Cardiology, Tivoli University Hospital, La Louvière, Belgium. adaminian@hotmail.com
authors.forename: Adel
authors.initials: A
authors.lastname: Aminian
authors.forename: Karim Zouaoui
authors.initials: KZ
authors.lastname: Boudjeltia
authors.forename: Sajida
authors.initials: S
authors.lastname: Babar
authors.forename: Pierre
authors.initials: P
authors.lastname: Van Antwerpen
authors.forename: Pascal
authors.initials: P
authors.lastname: Lefebvre
authors.forename: Vincent
authors.initials: V
authors.lastname: Crasset
authors.forename: Attilio
authors.initials: A
authors.lastname: Leone
authors.forename: Jean
authors.initials: J
authors.lastname: Ducobu
authors.forename: Alain
authors.initials: A
authors.lastname: Friart
authors.forename: Michel
authors.initials: M
authors.lastname: Vanhaeverbeek
mesh_terms: D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000201:enzymology* / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D015331:Cohort Studies; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D007781:Lactoferrin / Q000097:blood; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000201:enzymology* / Q000628:therapy; D018375:Neutrophil Activation / Q000502:physiology; D009195:Peroxidase / Q000097:blood*; D015607:Stents; D013997:Time Factors
chemical_list: D015415:Biomarkers; D015850:Interleukin-6; D002097:C-Reactive Protein; D009195:Peroxidase; D007781:Lactoferrin